This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Analysts Conflicted on These Healthcare Names: Teleflex (TFX) and Blueprint Medicines (BPMC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX – Research Report) and Blueprint Medicines (BPMC – Research Report).
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Read More on TFX:
Disclaimer & DisclosureReport an Issue
- Teleflex Reports Q1 2025 Results and Strategic Plans
- Teleflex’s Earnings Call: Mixed Sentiments and Strategic Moves
- Teleflex’s Mixed Outlook: Strong Revenue Performance Amid Tariff Challenges and Strategic Uncertainty
- Teleflex’s Mixed Financial Outlook: Hold Rating Amid Tariff Challenges and Segment Variability
- Teleflex price target lowered to $145 from $160 at Jefferies
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
